Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of [14C] tavapadon.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Tavapadon tablet

Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily [QD] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)

Drug - Tavapadon [14C] suspension

Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of [14C] Tavapadon on Day 16

Additional Information

Official Study Title

An Open-label Trial to Evaluate the Absorption, Metabolism, and Excretion of a Single Dose of [14C]-Tavapadon in Healthy Adult Male Subjects at Steady State

Clinical Trial ID

NCT04241393

ParticipAid ID

bo23Na